PRESS RELEASE: Signature Oncology to Appoint Glenn Gilbert as CEO & Managing Director

Signature Oncology Pty Ltd (“Signature” or “the Company”), an innovative cancer diagnostics platform company focused on the development of unique gene signature assays that empowers clinician decision making and advances patient care, today announces the appointment of Mr Glenn Gilbert as CEO and Managing Director of the Company, effective 9 June 2023.

Commencing 9 May 2023, Mr Gilbert will act as an exclusive consultant to Signature while the Company completes a capital raise to fund the next development phase of its proprietary gene signature melanoma diagnostic. Following the completion of the capital raise, Mr Gilbert will then assume the role of CEO and Managing Director of the Company.

Mr Gilbert has over 18 years of experience in the healthcare sector (including pharmaceutical, medical device (Rx and OTC) and IVD industries) across domestic and international markets. He was the former CEO and Managing Director at Rhythm Biosciences (ASX: RHY), a transformative and predictive cancer diagnostics technology company, developing and commercialising low cost, global, mass-market blood tests for cancer detection. During his tenure, he grew the market capitalisation from circa $3 million in March 2020 to peak of circa $400 million. Prior to Rhythm, Mr Gilbert held leadership roles at CSL Seqirus (ASX: CSL), and Medical Developments International (ASX: MVP) and has extensive business experience across the UK, Europe, Asia, North and South America.

Dr Thomas Duthy, Chairman of Signature said “We are delighted to have appointed someone of the calibre and experience of Glenn to Signature Oncology as our inaugural CEO and Managing Director. Glenn has a demonstrated track record of generating significant shareholder returns through focussed commercial development success, in parallel with sound financial execution through timely capital raisings and prudent balance sheet management. Under his leadership, we look forward to accelerating the commercialisation of our first gene signature diagnostic test for advanced melanoma, which has shown utility in multiple trials by identifying those patients who are likely to respond most favourably to immune checkpoint inhibitors.”

Mr Glenn Gilbert, Incoming CEO of Signature said “40-50% of advanced melanoma patients are unresponsive to checkpoint inhibitors, otherwise known as immunotherapy drugs. There is a significant market opportunity for our proprietary diagnostic test to guide clinician decision making, reduce healthcare costs and prevent patient exposure to unnecessary and unpleasant side-effects. In addition, those pharmaceutical companies with novel checkpoint inhibitors looking to select responders in clinical trials and become a standard treatment in the emerging neoadjuvant melanoma setting could also benefit from our novel diagnostic.”

Authority
This announcement has been authorised for release by the Board of Signature Oncology Pty Ltd.

For more information please contact:

Investors/Media
Dr Thomas Duthy
Chairman
[email protected]
+61 (0)402 493 727

Investors/Media
Mr Glenn Gilbert
Incoming CEO & Managing Director
[email protected]
+61 (0) 419 879 929

About Signature Oncology
Signature Oncology was founded in 2022 with a mission to develop a novel diagnostics platform for personalising cancer therapy. The Company is focused on the development of new cancer diagnostic tests, which are based on an innovative technology platform in melanoma that empowers clinician decision making and advances patient care and treatment. The proprietary technology is based on unique Interferon Gamma (IFNG/IFN-) signature in melanoma, which is a large, growing market characterised by high-cost drug therapies, which are often prescribed without careful analysis of patients who are most likely to benefit from the intervention.
For more information about Signature Oncology please visit: https://signatureoncology.com/